Trial Profile

A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belatacept (Primary) ; Corticosteroids (Primary) ; Mycophenolic acid (Primary) ; Siplizumab (Primary) ; Antithymocyte globulin; Tacrolimus
Indications Renal transplant rejection
Focus Adverse reactions
Acronyms ASCEND
Sponsors ITBMed Biopharmaceuticals

17 Apr 2025 Status changed from recruiting to active, no longer recruiting.
09 Jan 2024 Planned End Date changed from 1 Sep 2025 to 1 Oct 2026.
09 Jan 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Jul 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com